You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Limited resection of pancreatic cancer in high-risk patients can result in a second primary
  1. T P Potjer1,
  2. D K Bartsch2,
  3. E P Slater2,
  4. E Matthäi2,
  5. B A Bonsing3,
  6. H F A Vasen4
  1. 1 Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
  2. 2 Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany
  3. 3 Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
  4. 4 Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Dr H F A Vasen, Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, The Netherlands; hfavasen{at}stoet.nl

https://doi.org/10.1136/gutjnl-2015-309568

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dear Editor,

    We read with interest the paper by Canto and coworkers recently published in Gut that provided guidelines for the management of individuals with a high risk for pancreatic ductal adenocarcinoma (PDAC).1 Although indications for surgery are discussed, no recommendations are given regarding the extent of surgery, that is, partial pancreatectomy (PP) or total pancreatectomy (TP), in cases with a small screen-detected PDAC. This is an important issue because it seems very likely that a hereditary background increases the risk for a second primary cancer of the pancreas. Here, we describe two high-risk individuals who developed a second primary tumour after a PP of an early-stage cancer.

    Patient 1 is a 62-year-old woman with the common Dutch ‘p16-Leiden’ founder mutation in the CDKN2A gene and a medical history of melanoma at age 56. This patient was enrolled …

    View Full Text

    Footnotes

    • Contributors Design of manuscript: TPP, HFAV. Writing of first draft of manuscript: TPP, HFAV, DKB. Editing the first draft and approving the final draft of the manuscript: DKB, EPS, EM, BAB, HFAV.

    • Funding This work was supported by the ZOLEON foundation (no. 12.09 to HFAV).

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.